Advertisement
Latest News
- Uppsala startup wins Gates Foundation support
- FDA wins GLP‑1 dispute – setback for makers of copycat drugs
- Oxcia secures EMA orphan drug status for novel IPF therapy
- Roche’s first ‘ready-negotiated’ price wins TLV approval
- Breakthrough in pancreatic cancer – new drug wins FDA approval
- EU rejects calls to phase out PVC in pharma packaging
- Ambu obtains US and EU clearances for new neurology solutions
- Boston Scientific drops after new cyberattack – “A global disruption”
- Licensing breakthroughs propel AlzeCure to first‑ever profit
- Jazz wins approval for potential $2bn blockbuster
- Lundbeck enters into AI partnership in the US
- From space to the world’s first fertility app: “Physics had always been my only dream”
- Long‑acting asthma drug Exdensur gains reimbursement in Sweden
- Nordic partnership aims for faster cancer diagnostics – ”Minutes instead of weeks”
- Leqembi Iqlik launches as start‑dose option
- Cyberattacks surge – the medtech companies hit this year
- BioArctic chair: “First, you need to know where you’re going”
- Roche bets on muscle‑preserving obesity drug in $2.3 billion deal
- Study: Nearly 90% of biomedical papers show signs of AI assistance
- A single inhaler, three medicines: EU approves new asthma therapy
- EU backs Lundbeck’s Cushing’s drug candidate
- Sanofi Sweden: ”We will work for more clinical trials”
- Upgraded outlook sends Bavarian Nordic shares higher
- The vaccine has saved 94 million lives – but measles is spreading again
- Implantica secures FDA approval: “Culmination of many years of development”
- Lilly launches taRNA vaccine partnership
- Isotope deal boosts Uppsala radiotherapy company
- Melanoma data sends Moderna shares skyrocketing
- Coloplast delays introduction of new incontinence system
- “We develop vaccines no one else is developing”
- CEO change at Bico – ”The timing is right”
- BioArctic steps into cancer research with new collaboration
- New FDA setback for Xspray – stock plunges
- Trump expected to pick Heidi Overton to lead the FDA
- LEO Pharma acquires dermatology drug for 435 million USD
- Pila Pharma cleared to begin obesity trial
- Life sciences fuel Greater Copenhagen's economic growth
- Sanofi cuts 229 jobs following $9.1bn acquisition
- Evaxion drops solid tumour vaccine to advance new glioblastoma program
- CAR‑T developer Elicera appoints new CEO
- Potions, Placebos and Perilous Practices – Macabre Mistakes in the History of Medicine
- “Ozempic babies” – myth or reality?
- Hacker group claims Chinese bid for stolen Novo data
- Lantheus challenges Eli Lilly with FDA-approved Alzheimer’s tracer
- AstraZeneca scraps late‑stage study – and reports dual successes in lung cancer
- Life Science Nordic launches – bringing Nordic life science news under one roof
- Hansa chair: “Too many boards spend far too much time looking inwards”
- EMA opens review of Europe’s first potential Lyme disease vaccine
- Tuff vecka för Fresenius Kabi – dubbla återkallanden
- Ny finanschef till Biolamina
- Thermo Fishers mikrobiologiverksamhet byter ägare
- Phase III win for LSD‑based anxiety drug
- EU approves Rinvoq for severe patchy hair loss
- Lilly sues six companies over black market sales of experimental weight loss drug
- Läkemedel mot reumatism får grönt ljus för håravfall
- Low-profile Danish biotech recruits Mikael Dolsten
- Framgång i fas III för LSD-baserad tablett mot ångest
- Dansk doldis värvar Mikael Dolsten
- Eli Lilly till domstol för att stoppa svarthandel med ”triple-G”
- Nyt fra bestyrelser og direktioner i medtechbranchen
- WSA får ikke fornyet stor kontrakt med amerikansk managed care-kunde
- CF drug flops in phase II — shares collapse
- XVIVO’s heart technology receives CE certificates
- Sobi strengthens cancer portfolio with $580m deal
- Saniona’s neurology collaboration advances as AstronauTx Exercises acquisition option
- Carola Lemne: “You only know afterwards whether you made the right choice”
- Elicera reports strong CAR‑T-Data – shares rise
- Demant-topchef: – Der er momentum i alle forretningsområder
- Demant løber klart fra konsensus og opjusterer
- CAR-T-bolag lyfte efter nya data
- Xvivos hjärtteknologi CE-märks – ”Ett avgörande ögonblick”
- Jazz stärker epilepsiportföljen med miljardköp
- CF-projekt föll i fas II – aktien kollapsade
- Moberg Pharma möblerar om i ledningen inför lanseringsfas
- Uppgifter: Astra Zenecas jätteaffär med BMS föll efter aktieras
- Novo i AI-samarbete med Amazon-bolag
- Sanionas partner utnyttjar option – ”Starkt erkännande”
- Carola Lemne: ”Man vet först i efterhand om man valde rätt”
- Scandinavia Medical Solutions leverer storordre i nyt marked
- Optakt til Demant-regnskab: Opjustering er bredt ventet i markedet
- Sobi stärker cancerportföljen med miljardavtal
- Snabbspår för Bioinvent i USA – ”Bekräftar vår strategi”
- Tredje gången gillt – FDA godkänner ratad hudcancerbehandling
- Sommerens rokader i bestyrelser og direktioner i medtech-branchen
- Astra Zeneca bygger fabrik ihop med kinesisk partner
- FDA godkänner första läkemedlet som angriper orsaken till narkolepsi
- Chemometec-formand erkender fejlrekruttering: Ny CFO skal styrke det operationelle fokus
- FDA:s vändning – godkänner mRNA-vaccin mot influensa
- Medicover säljer indisk verksamhet – får 8 miljarder
- Eli Lillys resultat klart bättre än väntat
- Fusionsplaner dementeras – Astra Zeneca stiger
- Vägledande utslag i USA: Ingen skyldighet för läkemedelsbolag att skynda på innovation
- Novo Nordisk höjer helårsutsikter
- Ännu ett cyberangrepp – hackare stal patientdata av Amgen
- Alligator avbryter huvudprojekt och skär ned – ”Svårt men nödvändigt beslut”
- Ny robot skal hjælpe børn med autisme
Advertisement
Advertisement
Advertisement
News from our members
- Your UKRP Partner for Medical Device Market Access in the UK
- Kostnadseffektiv och driftsäker nivåmätning med Rosemount 1208
- Medical Device Software Process Design: Why IEC 62304 Matters
- Kostnadseffektiv automation för framtidens företag
- Your Partner for Clinical Study Submissions and Regulatory Interactions
Most read
Advertisement
Advertisement
BREAKING